PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, has agreed to acquire a majority stake in Agilera Pharma AS from the Institute for Energy Technology (IFE) in Norway, marking a significant step forward in the company’s strategy to create the first fully-integrated, global CDMO specializing in radiopharmaceutical therapies.

Agilera has been a partner for major pharmaceutical companies for more than a decade, manufacturing commercial radiopharmaceutical therapies across the United States, Europe, and Asia. With more than 600,000 commercial therapeutic doses delivered to more than 40 countries, Agilera further advances PharmaLogic’s commitment to innovation and excellence in the industry.

“PharmaLogic’s acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field,” said Etienne Montagut, President of PharmaLogic. “By combining our expertise with Agilera’s industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments. We’re thrilled to welcome Agilera’s very talented team to PharmaLogic and to take the lead in expanding our presence in Europe.”

Under the terms of the agreement, Agilera will complement PharmaLogic’s existing manufacturing platform for therapeutics, enhancing the company’s ability to deliver radiopharmaceutical solutions. PharmaLogic is committed to investing in the expansion of Agilera’s CDMO capabilities, strengthening its infrastructure, and scaling its manufacturing footprint to meet rising global demand for radiopharmaceutical therapeutics. This acquisition establishes PharmaLogic as the only CDMO with a global presence actively producing and distributing one of the main commercially-approved radiopharmaceutical therapies for major pharmaceutical companies.

“With PharmaLogic as a new owner beside IFE, this will enable further investments in the business to ensure that we have the right, available capacity to take on new customer projects and thus achieve faster adaptation to the promising market opportunities,” said Erik Flatmark, CEO of Agilera.

Closing of the transaction is subject to customary conditions, including regulatory approvals, license transfers and certain third-party consents. The acquisition is expected to close in June of 2025.

More Pharma Industry Acquisitions

Don’t miss Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.